The Company combines its capabilities in molecular, cellular and structural biology, high-throughput drug screening, medicinal chemistry and genomics to develop products with commercial potential. The Company is evaluating Cialis, a small molecule compound that inhibits the phosphodiesterase type five enzyme for the treatment of male erectile dysfunction and female sexual dysfunction. The Company is also evaluating Pafase, a recombinant human serum protein, for the treatment of sepsis and other diseases characterized by increased activity of platelet-activating factor. Revenues reflect an increase in collaborative research and development revenues.
Net loss reflects an increase in equity in losses of affiliates.
All Rights Reserved. Privacy Policy - Terms of Service Company information Copyright Market Guide . Some event data provided by StreetEvents . Data and information is provided for informational purposes only, and is not intended for trading purposes.